Pacific Wealth Management
- SEC CIK
- 0001852338
- Latest filing
- Oct 5, 2026
Holdings in Q3 2026
Holdings as of Sep 30, 2026, filed Oct 5, 2026. Long positions only; changes compare share counts with Q2 2026.
- Positions
- 20
- +1 vs. Q2 2026
- Portfolio value
- $227.3M
- +$1.80M (+0.8%) vs. Q2 2026
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| SPYSPDR S&P 500 ETF Trust | ETF | 175,280 | $133.7M | 58.8% | +586+0.3% | Added | History |
| Nomura ETF Tr555927508 | FOCU EM MKTS ETF | 490,243 | $32.2M | 14.2% | +9,970+2.1% | Added | – |
| iShares U.S. Treasury Bond ETF46429B267 | ETF | 497,893 | $10.9M | 4.8% | −178,586−26.4% | Reduced | – |
| ABBVAbbVie Inc. | Stock | 38,039 | $9.95M | 4.4% | −229−0.6% | Reduced | History |
| iShares Tr464287440 | 7-10 YR TRSY BD | 101,981 | $9.11M | 4.0% | −56,930−35.8% | Reduced | – |
| Vanguard Intermediate-Term Corporate Bond ETF92206C870 | ETF | 108,638 | $8.51M | 3.7% | +10,368+10.6% | Added | – |
| State Street Health Care Select Sector SPDR ETF81369Y209 | ETF | 33,577 | $5.66M | 2.5% | +33,577 | New | – |
| Global X FDS37954Y632 | ARTIFICIAL ETF | 84,913 | $5.53M | 2.4% | +84,913 | New | – |
| INTCIntel Corp | Stock | 40,802 | $4.91M | 2.2% | +278+0.7% | Added | History |
| ABTAbbott Laboratories | Stock | 23,009 | $2.27M | 1.0% | −974−4.1% | Reduced | History |
| GLDSPDR Gold Trust | ETF | 3,331 | $1.27M | 0.6% | +3,331 | New | History |
| AAPLApple Inc. | Stock | 1,922 | $640.1K | 0.3% | −237−11.0% | Reduced | History |
| MSFTMicrosoft Corp | Stock | 963 | $493.9K | 0.2% | −318−24.8% | Reduced | History |
| ONTOOnto Innovation Inc. | COM | 1,287 | $396.2K | 0.2% | 00.0% | Unchanged | History |
| iShares Tr46429B291 | A RATE CP BD ETF | 7,499 | $337.4K | 0.1% | 00.0% | Unchanged | – |
| Dimensional ETF Trust25434V617 | WORLD EQUITY ETF | 4,059 | $334.1K | 0.1% | +4,059 | New | – |
| Vanguard S&P 500 ETF922908363 | ETF | 463 | $324.5K | 0.1% | −15−3.1% | Reduced | – |
| BRK.BBerkshire Hathaway Inc | Stock | 612 | $304.7K | 0.1% | −40−6.1% | Reduced | History |
| Invesco QQQ Trust Series I46090E103 | ETF | 412 | $304.6K | 0.1% | 00.0% | Unchanged | – |
| HALOHalozyme Therapeutics, Inc. | COM | 2,184 | $241.1K | 0.1% | −3,217−59.6% | Reduced | History |
Sold out since Q2 2026 (3)
Positions held at the end of Q2 2026 that are gone from this filing.